Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Buy

Jasper Therapeutics, Inc. Common Stock (JSPR)

Biological Products, (no Disgnostic Substances)

https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

2200 BRIDGE PKWY SUITE #102
REDWOOD CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/27/2021

Market Cap

276,368,192

Shares Outstanding

11,160,000

Weighted SO

11,157,526

Total Employees

N/A

Upcoming Earnings

08/09/2024

Beta

2.2200

Last Div

0.0000

Range

4.0-31.01

Chg

0.2200

Avg Vol

174335

Mkt Cap

276368192

Exch

NASDAQ

Country

US

Phone

650 549 1400

DCF Diff

10.0436

DCF

8.0564

Div Yield

0.0000

P/S

134.6824

EV Multiple

-2.5431

P/FV

2.7370

Div Yield %

0.0000

P/E

-4.3973

PEG

-0.6479

Payout

0.0000

Current Ratio

10.7946

Quick Ratio

10.7946

Cash Ratio

10.6098

DSO

44.4688

DIO

0.0000

Op Cycle

44.4688

DPO

944.0314

CCC

-899.5626

Gross Margin

0.4415

Op Margin

-33.2125

Pretax Margin

-30.4269

Net Margin

-30.4269

Eff Tax Rate

-0.0024

ROA

-0.5480

ROE

-0.6468

ROCE

-0.6562

NI/EBT

1.0000

EBT/EBIT

0.9161

EBIT/Rev

-33.2125

Debt Ratio

0.0203

D/E

0.0231

LT Debt/Cap

0.0127

Total Debt/Cap

0.0226

Int Coverage

217.7380

CF/Debt

-24.1261

Equity Multi

1.1358

Rec Turnover

8.2080

Pay Turnover

0.3866

Inv Turnover

0.0000

FA Turnover

0.5593

Asset Turnover

0.0180

OCF/Share

-3.7285

FCF/Share

-3.7559

Cash/Share

7.1277

OCF/Sales

-27.2300

FCF/OCF

1.0074

CF Coverage

-24.1261

ST Coverage

-54.3013

CapEx Coverage

-135.6214

Div&CapEx Cov

-135.6214

P/BV

2.7370

P/B

2.7370

P/S

134.6824

P/E

-4.3973

P/FCF

-4.9099

P/OCF

-4.9136

P/CF

-4.9136

PEG

-0.6479

P/S

134.6824

EV Multiple

-2.5431

P/FV

2.7370

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 14, 14:00 Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria GlobeNewswire Inc. Mar 01, 17:45 Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting GlobeNewswire Inc. Dec 18, 16:30 Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 GlobeNewswire Inc. Dec 10, 11:00 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

Revenue Product Segmentation